HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Switches, Pediatric Products Highlight OTC Outlook In Independent Pharmacies

This article was originally published in The Pink Sheet

Executive Summary

OTC cold and allergy product sales lead the health, wellness and beauty segment in 16,000 US independent pharmacies, says Hamacher Resource Group. Vitamins and supplements, which lead other categories in chain retail pharmacies, are the No. 2 category in independent pharmacies.

You may also be interested in...



Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump

J&J says Tylenol outpaced other analgesics in the first quarter as its OTC franchise grew 1.4% on a reported basis to $1.01 bn. CFO Dominic Caruso said new consumer products will add 2 points of incremental growth to the segment in 2017.

Technology Gap Separates OTC Drug Firms From Self-Care Sales Growth

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine

FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel